Category: 136725-55-8

Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 136725-55-8, is researched, Molecular C4H9ClFN, about Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors, the main research direction is DYRK inhibitor ligand efficient.Reference of (R)-(-)-3-Fluoropyrrolidine Hydrochloride.

Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted interest as a target for the treatment of neurodegenerative diseases, including Alzheimer′s disease (AD) and Down′s syndrome. Recently, the inhibition of DYRK1A has been investigated as a potential treatment for diabetes, while DYRK1A′s role as a mediator in the cell cycle has garnered interest in oncol. indications. Structure-activity relationship (SAR) anal. in combination with high-resolution X-ray crystallog. leads to a series of pyrazolo[1,5-b]pyridazine inhibitors with excellent ligand efficiencies, good physicochem. properties, and a high degree of selectivity over the kinome. Compound 11 (I) exhibited good permeability and cellular activity without P-glycoprotein liability, extending the utility of 11 in an in vivo setting. These pyrazolo[1,5-b]pyridazines are a viable lead series in the discovery of new therapies for the treatment of diseases linked to DYRK1A function.

In some applications, this compound(136725-55-8)Reference of (R)-(-)-3-Fluoropyrrolidine Hydrochloride is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.

Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem

SDS of cas: 136725-55-8. The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: (R)-(-)-3-Fluoropyrrolidine Hydrochloride, is researched, Molecular C4H9ClFN, CAS is 136725-55-8, about Fluorine in medicinal chemistry: β-fluorination of peripheral pyrrolidines attached to acridine ligands affects their interactions with G-quadruplex DNA. Author is Campbell, Nancy H.; Smith, Daniel L.; Reszka, Anthony P.; Neidle, Stephen; O’Hagan, David.

Comparative X-ray structure studies reveal that C-F bond incorporation into the peripheral pyrrolidine moieties of the G-quadruplex DNA binding ligand BSU6039 leads to a distinct pyrrolidine ring conformation, relative to the non-fluorinated analog, and with a different binding mode involving reversal of the pyrrolidinium N+-H orientation.

As far as I know, this compound(136725-55-8)SDS of cas: 136725-55-8 can be applied in many ways, which is helpful for the development of experiments. Therefore many people are doing relevant researches.

Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem

Kroth, Heiko; Oden, Felix; Molette, Jerome; Schieferstein, Hanno; Gabellieri, Emanuele; Mueller, Andre; Berndt, Mathias; Sreenivasachary, Nampally; Serra, Andreia Monica; Capotosti, Francesca; Schmitt-Willich, Heribert; Hickman, David; Pfeifer, Andrea; Dinkelborg, Ludger; Stephens, Andrew published the article 《PI-2620 Lead Optimization Highlights the Importance of Off-Target Assays to Develop a PET Tracer for the Detection of Pathological Aggregated Tau in Alzheimer′s Disease and Other Tauopathies》. Keywords: PET imaging tracer preparation Tau aggregation Alzheimer’s palsy Pick’s.They researched the compound: (R)-(-)-3-Fluoropyrrolidine Hydrochloride( cas:136725-55-8 ).Category: pyridazine. Aromatic heterocyclic compounds can be divided into two categories: single heterocyclic and fused heterocyclic. In addition, there is a lot of other information about this compound (cas:136725-55-8) here.

The first candidate PI-2014 was tested in healthy controls and subjects with Alzheimer′s disease (AD). As PI-2014 displayed off-target binding to monoamine oxidase A (MAO-A), a new lead with improved binding to Tau and decreased MAO-A binding was required. For compound optimization, Tau binding assays based on both human AD brain homogenate and Tau-paired helical filaments were employed. Furthermore, two MAO-A screening assays based on (1) human-recombinant MAO-A and (2) displacement of 2-fluoro-ethyl-harmine from mouse brain homogenate were employed. Removing the N-Me group from the tricyclic core resulted in compounds displaying improved Tau binding. For the final round of optimization, the cyclic amine substituents were replaced by pyridine derivatives PI-2620 (2-(2-fluoropyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c′]dipyridine) emerged as a best candidate displaying high Tau binding, low MAO-A binding, high brain uptake, and fast and complete brain washout. Furthermore, PI-2620 showed Tau binding on brain sections from corticobasal degeneration, progressive supranuclear palsy, and Pick′s disease.

As far as I know, this compound(136725-55-8)Category: pyridazine can be applied in many ways, which is helpful for the development of experiments. Therefore many people are doing relevant researches.

Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem

The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: (R)-(-)-3-Fluoropyrrolidine Hydrochloride(SMILESS: Cl.F[C@@H]1CCNC1,cas:136725-55-8) is researched.Application of 21778-81-4. The article 《Novel Human Neutral Sphingomyelinase 2 Inhibitors as Potential Therapeutics for Alzheimer’s Disease》 in relation to this compound, is published in Journal of Medicinal Chemistry. Let’s take a look at the latest research on this compound (cas:136725-55-8).

Neutral sphingomyelinase 2 (nSMase2) catalyzes the cleavage of sphingomyelin to phosphorylcholine and ceramide, an essential step in the formation and release of exosomes from cells that is critical for intracellular communication. Chronic increase of brain nSMase2 activity and related exosome release has been implicated in various pathol. processes, including the progression of Alzheimer’s disease (AD), making nSMase2 a viable therapeutic target. Recently, we identified phenyl(R)-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b] pyridazin-8-yl) pyrrolidin-3-yl)-carbamate 1 (PDDC)(I), the first nSMase2 inhibitor which possesses both favorable pharmacodynamics and pharmacokinetic (PK) parameters, including substantial oral bioavailability, brain penetration and significant inhibition of exosome release from the brain in vivo. Herein we demonstrate efficacy of 1 (PDDC) in a mouse model of AD and detail extensive structure-activity relationship (SAR) studies with 70 analogs, unveiling several that exert similar or higher activity against nSMase2 with favorable pharmacokinetic properties.

As far as I know, this compound(136725-55-8)Reference of (R)-(-)-3-Fluoropyrrolidine Hydrochloride can be applied in many ways, which is helpful for the development of experiments. Therefore many people are doing relevant researches.

Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem

Recommanded Product: 136725-55-8. The reaction of aromatic heterocyclic molecules with protons is called protonation. Aromatic heterocycles are more basic than benzene due to the participation of heteroatoms. Compound: (R)-(-)-3-Fluoropyrrolidine Hydrochloride, is researched, Molecular C4H9ClFN, CAS is 136725-55-8, about Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors. Author is Henderson, Scott H.; Sorrell, Fiona; Bennett, James; Fedorov, Oleg; Hanley, Marcus T.; Godoi, Paulo H.; Ruela de Sousa, Roberta; Robinson, Sean; Ashall-Kelly, Alexander; Hopkins Navratilova, Iva; Walter, Daryl S.; Elkins, Jonathan M.; Ward, Simon E..

Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted interest as a target for the treatment of neurodegenerative diseases, including Alzheimer′s disease (AD) and Down′s syndrome. Recently, the inhibition of DYRK1A has been investigated as a potential treatment for diabetes, while DYRK1A′s role as a mediator in the cell cycle has garnered interest in oncol. indications. Structure-activity relationship (SAR) anal. in combination with high-resolution X-ray crystallog. leads to a series of pyrazolo[1,5-b]pyridazine inhibitors with excellent ligand efficiencies, good physicochem. properties, and a high degree of selectivity over the kinome. Compound 11 (I) exhibited good permeability and cellular activity without P-glycoprotein liability, extending the utility of 11 in an in vivo setting. These pyrazolo[1,5-b]pyridazines are a viable lead series in the discovery of new therapies for the treatment of diseases linked to DYRK1A function.

As far as I know, this compound(136725-55-8)Recommanded Product: 136725-55-8 can be applied in many ways, which is helpful for the development of experiments. Therefore many people are doing relevant researches.

Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem

In organic chemistry, atoms other than carbon and hydrogen are generally referred to as heteroatoms. The most common heteroatoms are nitrogen, oxygen and sulfur. Now I present to you an article called PI-2620 Lead Optimization Highlights the Importance of Off-Target Assays to Develop a PET Tracer for the Detection of Pathological Aggregated Tau in Alzheimer′s Disease and Other Tauopathies, published in 2021-09-09, which mentions a compound: 136725-55-8, mainly applied to PET imaging tracer preparation Tau aggregation Alzheimer’s palsy Pick’s, Recommanded Product: (R)-(-)-3-Fluoropyrrolidine Hydrochloride.

The first candidate PI-2014 was tested in healthy controls and subjects with Alzheimer′s disease (AD). As PI-2014 displayed off-target binding to monoamine oxidase A (MAO-A), a new lead with improved binding to Tau and decreased MAO-A binding was required. For compound optimization, Tau binding assays based on both human AD brain homogenate and Tau-paired helical filaments were employed. Furthermore, two MAO-A screening assays based on (1) human-recombinant MAO-A and (2) displacement of 2-fluoro-ethyl-harmine from mouse brain homogenate were employed. Removing the N-Me group from the tricyclic core resulted in compounds displaying improved Tau binding. For the final round of optimization, the cyclic amine substituents were replaced by pyridine derivatives PI-2620 (2-(2-fluoropyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c′]dipyridine) emerged as a best candidate displaying high Tau binding, low MAO-A binding, high brain uptake, and fast and complete brain washout. Furthermore, PI-2620 showed Tau binding on brain sections from corticobasal degeneration, progressive supranuclear palsy, and Pick′s disease.

As far as I know, this compound(136725-55-8)Recommanded Product: (R)-(-)-3-Fluoropyrrolidine Hydrochloride can be applied in many ways, which is helpful for the development of experiments. Therefore many people are doing relevant researches.

Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem

Electric Literature of C4H9ClFN. The reaction of aromatic heterocyclic molecules with protons is called protonation. Aromatic heterocycles are more basic than benzene due to the participation of heteroatoms. Compound: (R)-(-)-3-Fluoropyrrolidine Hydrochloride, is researched, Molecular C4H9ClFN, CAS is 136725-55-8, about Fluorine Substitution Induced High Tc of Enantiomeric Perovskite Ferroelectrics: (R)- and (S)-3-(Fluoropyrrolidinium)MnCl3. Author is Ai, Yong; Chen, Xiao-Gang; Shi, Ping-Ping; Tang, Yuan-Yuan; Li, Peng-Fei; Liao, Wei-Qiang; Xiong, Ren-Gen.

The past decade has witnessed much progress in designing mol. ferroelecs., whose intrinsic mech. flexibility, structural tunability, and easy processability are desirable for next-generation flexible and wearable electronic devices. However, an obstacle in expanding their promising applications in nonvolatile memory elements, capacitors, and sensors is effectively modulating the Curie temperature (Tc). Here, taking advantage of fluorine substitution on the reported mol. ferroelec., (pyrrolidinium)MnCl3, we present enantiomeric perovskite ferroelecs., namely, (R)- and (S)-3-(fluoropyrrolidinium)MnCl3. The close van der Waal’s radii and the similar steric parameters between H and F atoms ensure the min. disruption of the crystal structure, while their different electronegativity and polarizability can trigger significant changes in the phys. and chem. properties. As expected, the Tc gets successfully increased from 295 K in (pyrrolidinium)MnCl3 to 333 K in these two homochiral compounds Such a dramatic enhancement of 38 K signifies an important step toward designing high-Tc mol. ferroelecs. In the light of the conceptually new idea of fluorine substitution, one could look forward to a continuous succession of new mol. ferroelec. materials and technol. developments.

As far as I know, this compound(136725-55-8)Electric Literature of C4H9ClFN can be applied in many ways, which is helpful for the development of experiments. Therefore many people are doing relevant researches.

Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem

Ai, Yong; Chen, Xiao-Gang; Shi, Ping-Ping; Tang, Yuan-Yuan; Li, Peng-Fei; Liao, Wei-Qiang; Xiong, Ren-Gen published the article 《Fluorine Substitution Induced High Tc of Enantiomeric Perovskite Ferroelectrics: (R)- and (S)-3-(Fluoropyrrolidinium)MnCl3》. Keywords: manganese chloride fluoropyrrolidinium fluorine substitution enantiomeric perovskite ferroelec.They researched the compound: (R)-(-)-3-Fluoropyrrolidine Hydrochloride( cas:136725-55-8 ).Application of 136725-55-8. Aromatic heterocyclic compounds can be divided into two categories: single heterocyclic and fused heterocyclic. In addition, there is a lot of other information about this compound (cas:136725-55-8) here.

The past decade has witnessed much progress in designing mol. ferroelecs., whose intrinsic mech. flexibility, structural tunability, and easy processability are desirable for next-generation flexible and wearable electronic devices. However, an obstacle in expanding their promising applications in nonvolatile memory elements, capacitors, and sensors is effectively modulating the Curie temperature (Tc). Here, taking advantage of fluorine substitution on the reported mol. ferroelec., (pyrrolidinium)MnCl3, we present enantiomeric perovskite ferroelecs., namely, (R)- and (S)-3-(fluoropyrrolidinium)MnCl3. The close van der Waal’s radii and the similar steric parameters between H and F atoms ensure the min. disruption of the crystal structure, while their different electronegativity and polarizability can trigger significant changes in the phys. and chem. properties. As expected, the Tc gets successfully increased from 295 K in (pyrrolidinium)MnCl3 to 333 K in these two homochiral compounds Such a dramatic enhancement of 38 K signifies an important step toward designing high-Tc mol. ferroelecs. In the light of the conceptually new idea of fluorine substitution, one could look forward to a continuous succession of new mol. ferroelec. materials and technol. developments.

As far as I know, this compound(136725-55-8)Application of 136725-55-8 can be applied in many ways, which is helpful for the development of experiments. Therefore many people are doing relevant researches.

Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem

So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic.Caldwell, Charles G.; Chen, Ping; He, Jiafang; Parmee, Emma R.; Leiting, Barbara; Marsilio, Frank; Patel, Reshma A.; Wu, Joseph K.; Eiermann, George J.; Petrov, Aleksandr; He, Huaibing; Lyons, Kathryn A.; Thornberry, Nancy A.; Weber, Ann E. researched the compound: (R)-(-)-3-Fluoropyrrolidine Hydrochloride( cas:136725-55-8 ).Application of 136725-55-8.They published the article 《Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors》 about this compound( cas:136725-55-8 ) in Bioorganic & Medicinal Chemistry Letters. Keywords: cyclohexylglycylfluoropyrrolidine preparation dipeptidyl peptidase IV inhibitor. We’ll tell you more about this compound (cas:136725-55-8).

Amides derived from fluorinated pyrrolidines and 4-substituted cyclohexylglycine analogs have been prepared and evaluated as inhibitors of dipeptidyl dipeptidase IV (DP-IV). Analogs which incorporated (S)-3-fluoropyrrolidine showed good selectivity for DP-IV over quiescent cell proline dipeptidase (QPP). Amide I had good pharmacokinetic properties and was orally active in an oral glucose tolerance test in lean mice.

In addition to the literature in the link below, there is a lot of literature about this compound((R)-(-)-3-Fluoropyrrolidine Hydrochloride)Application of 136725-55-8, illustrating the importance and wide applicability of this compound(136725-55-8).

Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem

The chemical properties of alicyclic heterocycles are similar to those of the corresponding chain compounds. Compound: (R)-(-)-3-Fluoropyrrolidine Hydrochloride, is researched, Molecular C4H9ClFN, CAS is 136725-55-8, about Discovery of novel 4-phenyl-2-(pyrrolidinyl)nicotinamide derivatives as potent Nav1.1 activators, the main research direction is phenyl pyrrolidinyl nicotinamide derivative preparation sodium channel CNS disease; Dravet syndrome phenyl pyrrolidinyl nicotinamide derivative preparation; BBB penetration; Dravet syndrome; Na(v)1.1 activator; Slow current decay of inactivation; Voltage-gated sodium channels.HPLC of Formula: 136725-55-8.

The voltage-gated sodium channel, Nav1.1, is predominantly expressed in parvalbumin-pos. fast spiking interneurons and has been genetically linked to Dravet syndrome. Starting from a high throughput screening hit isoxazole derivative 5, modifications of 5 via combinations of IonWorks and Q-patch assays successfully identified the nicotinamide derivative 4. Its increasing decay time constant (tau) of Nav1.1 currents at 0.03 μM along with significant selectivity against Nav1.2, Nav1.5, and Nav1.6 and acceptable brain exposure in mice was observed Compound 4 is a promising Nav1.1 activator that can be used to analyze pathophysiol. functions of the Nav1.1 channel towards treating various central nervous system diseases.

In addition to the literature in the link below, there is a lot of literature about this compound((R)-(-)-3-Fluoropyrrolidine Hydrochloride)HPLC of Formula: 136725-55-8, illustrating the importance and wide applicability of this compound(136725-55-8).

Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem